Novacyt SA (NCYT) – aksjekurser og nyheter

Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia

Om Novacyt SA

Administrerende direktørDavid Allmond

Ansatte228

Grunnlagt3. juli 2006

Hovedkontor-

Sektor-

Nettstednovacyt.com

Alle verdier i GBP	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	5,12 mill.	5,12 mill.	5,78 mill.	5,78 mill.
Varekostnad	2,61 mill.	2,61 mill.	2,56 mill.	2,56 mill.
Direkte driftskostnader	2,61 mill.	2,61 mill.	2,56 mill.	2,56 mill.
Utgifter til forskning og utvikling	1,03 mill.	1,03 mill.	1,06 mill.	1,06 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	4,69 mill.	4,69 mill.	4,65 mill.	4,65 mill.
Driftskostnader	5,54 mill.	5,54 mill.	5,66 mill.	5,66 mill.
Totale driftskostnader	8,16 mill.	8,16 mill.	8,22 mill.	8,22 mill.
Driftsinntekter	−3,04 mill.	−3,04 mill.	−2,44 mill.	−2,44 mill.
Andre ikke-operasjonelle inntekter	−23,00k	−23,00k	−47,50k	−47,50k
EBT inkludert uvanlige elementer	−10,16 mill.	−10,16 mill.	−2,91 mill.	−2,91 mill.
EBT uten uvanlige elementer	−2,52 mill.	−2,52 mill.	−2,80 mill.	−2,80 mill.
Kostnad for inntektsskatt	−1,81 mill.	−1,81 mill.	−49,50k	−49,50k
Faktisk avgiftssats	17,85 %	17,85 %	1,70 %	1,70 %
Andre driftskostnader	−180,50k	−180,50k	−44,00k	−44,00k
Nettoinntekt	−8,27 mill.	−8,27 mill.	−2,90 mill.	−2,90 mill.
Netto fortjenestemargin	−161,60 %	−161,60 %	−50,13 %	−50,13 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	149,00k	149,00k	63,00k	63,00k
Rentekostnader	−146,00k	−146,00k	−139,00k	−139,00k
Netto rentekostnader	3,00k	3,00k	−76,00k	−76,00k
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	3,46 mill.	3,46 mill.	−1,88 mill.	−1,88 mill.
Gevinst eller tap ved salg av eiendeler	−3,00k	−3,00k	8,00k	8,00k

Spør om hva som helst